MAPK8 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, similar to SUP-B15 cells, dasatinib is not able to inhibit phosphorylation of JNK in K562 cells, a Ph+ CML blast phase cell line, nor in patient-derived Ph+ B-ALL cells (Supplementary Fig. S1a, b, c, d, e and f).